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hkklmg aged therapy ia &its with mn@sllve heart failu&. 
M&o&. Tbtstudy Included 41 w&ents with idiopsthlc dilnted 
cdkmyog4lhy witi Jectiao r&m <0.4s lm&pm10l, 2  
ptials: p4KtbQ. 21 palkotsl wbw hcmadynandc %hlS was 
bwstlgated at rest and during suplm submsximnl exercise. st 
lmsztbx ud ruler 6 ud 12 months of IreUmed. Myocardkd 
membollsm wa3 evalu&d ln ” subset d 19 p&eats. 
Resrulu. Metqmlnl-(rrated pilttmb rqendnl favorably, BS 
eqwewl by lmpmwd exe&e mrdkx index ([mean f SDI 
drrbo 4.0 i 1.6 to 4.1 l 1.8 lttcr&ln oer ml. metoomlo14.3 f 
i.i to 5.4 + 1.9 Ilte&dn per m’, p = b.NHlli nnd &oke work 
bxkx @l&ao 44 t 26 to 41 zt 27 rmlm’, metapmtol35 + 16 to 
An increasing number of reports suggest improvement in 
cardiac function and hemadynamic status after beta- 
adtznergic blakiag agent treatment in patients with heart 
failure. The original observation of this therapy was reported 
Rrmetoprolol therapy (1.2). In recent years metoprolol and 
other beta-blockers have been used successfully G-6). The 
vasadilating properties cl other beta-blockers may have 
contributed to the observed improvemea:s. The role of 
beta.blockade per se ar a useful thenpy in heart failure has 
not been established. Ilp to the present time 17). there have 
inrrpased(plncr~al4LS10151*UcnmWg,mct~~lss~ 
29 to I65 * 37 mm “g, p = u.K@3, BE rsdl ari exweise OQW 
mnsumptioa iadrr ( ~=l~to474*~z~~~rm~, 
meloprolal4Ot 3: 272 to 507 f 298 mllmio pee ma, p = O&45). 
There was a ~igaifintrt ittweme in exercise d In the 
metoymlol group (63 * 38 s) campand with the g WP 
(-24 zt 42 s, (p = 0.01). Net myocardlat lactate extraction 
increased in ttle meioprolol group, suggesting tars myocsrdlat 
lschemia (ptswho 17 f 22 to 9.5 1: 6.4 mm&do, mrtoprolol 
-32 * 100 ta 42 f 45 m,,,.,U&. D = 0.031. Maheral lrvl OF . 
nweplnephrine tended to decrease st IV& and during ~:xer&e, 
whereas mywwdial net spillover was unchanged. 
Concfuslu~r. Estopmlcd lmpwwl bemodynamic :xtstus in 
patients with diMed cardiomyopathy 8t rest snd had a more 
prcnourwd elfixr during exercise. These positive owls were 
achieved along ;bltb inpmwd or &Me mywardial metabolic 
datn. 
(J Am CON Co&l 1994;23:1397-4?4J 
been no larxtr randomized trials. This study was performed 
to ivjestigate whether the positive effects previously noted 
in an open study (61 with regard to exercise hemodynamics 
and myocardial metabolism could be reproduced in a lang- 
term controlled trial. 
Methods 
Patients. The Vetopmlol in Dilated Cardiomyopathy 
Trial was completed in July 1992. The study recruited 383 
patients in 33 centers in Europe and North America. The 
study protow: was double-biind. placebo-controlled and 
randomized according tocenter and baseline ejection frac- 
tion <O.ZO or >0.20. The main results of the Metoprolol in 
Dilated Cardmmyopathy Trial Iii11 be published elsewhere 
(7). Inclusion criteria were symptomatic dilated cardiomy- 
apathy and ejection fraction <0.40. Exclusion criteria were 
coronary artery disease confirmed by coronary arteriogm- 
phy, systemic disease, insulin-dependent diabetes mellitus, 
excessive alcohol consumption, hypertension. signs of ac- 
tive myocard: ._) or other serious disease that might affect the 
prognosis of the patient. Before entering the study, the 
patients received a test dose of 5 mg of mstoprolol twice 
daily for 2 days. If this dosage was tolerated. the Datients 
were rando& assigned to receive metoprolol or plafebo for 
12 months. Twenty patients were randomized LO receive 
metoprolol. and 21 patients received placebo treatment. In 
the main study 4% of the patients were not included because 
of hemodynamic intolerance. Treatment was continued with 
increasing doses over 6 weeks according to the following 
schedule: week I,5 mg twice daily; week 2.5 mg three times 
a day; week 3, IO mg twice daily; week 4.25 mg twice daily: 
week 5,25 mp three times B day; week 6.50 mg twice deily; 
week 7 and onward, 50 mg three times a day. The final dose 
was detemined by the clinical status of the patient and 
possible adverse effects. The mean (-SD) final dose was 
130 * 26 mg in the metoproiol group and I16 + 52 mg in the 
placebo group ip = NS). In this repolt the pa&sots partici- 
paling in an optiona! substudy on exercise hemodynamic 
status are oresented. The baseline characteristics of the two 
groups I& shown in Table I. There were no statistically 
signihcant diierences in baseline variables between the two 
*oUps. 
ProtIll. The test drug was stopped 24 h before the 
investigation. All olher medications were maintained through- 
out the investigation. The patients were studied before 
inclusion and afw 6 and 12 months of treatment. On day 1, 
the patient perfomed a maximal sitting bicycle exercise test 
starting at 20 W. with iwements of 10 W/min. Radionuclide 
aogiocardiography was performed on day 2. On day 3, right 
heart catheterization was performed in the morning with the 
patient in a fasting state and without yremedicatian. A 
triple-lumen Swan-Gaoz potmonary artery catheter and a 
Wilton-Webster coronary sinus catheter were introduced 
percutaneously through ;he internal jugular vein. The cor- 
rect position of the coronary sinus catheter ws checked by 
fluoroscopic irjection of radiopaque medium and by tracings 
of flow curves. Ao arterial lie was obtained through the 
radial artery. F’ressures, flows and blood samples were 
obtained at rest. The patients then performed supine bicycle 
exercise at a tixed load of 50% of their maximal work load as 
determined from the exercise test performed on day 1. After 
4 min of exercise, pressures were recorded, and thereafter 
flow measurements and blood sampling were performed 
during wntinuous exercise. Cornnary sinus catheterization 
was optional io the swdy protocoI and was only performed ar 
the eoordioating center. 
Mwwemmts. Functional status was assessed according 
to New York Heart Association ftmctionxl classification. 
Left wtricular ejection tiaction was estimated imm cqui- 
librium mdionucl~c aogiogmphy. plows were measured by 
a tbermodilution technique. Cardiac output was measured in 
the pulmonary artery and was calculated by computers. The 
coronary sinus catheter war attached to a Wheatstone 
bridge, and changes in thermistor resistance cawed by cempr- 
atore changes were recorded on a Siemeos-EIema mingo- 
graph. Coronary sinus blood flow was calculated with a 
standard formula (8). Blwd sampks were obtained for 
analysis of oxygen content and catechdamioe and lactate 
concentration kvcls. Norepinephrioe and cpincphrioe levels 
in plasma were measured by high perfonoancc liquid chm- 
matography with elec~rochcmical detection (9). Lactate was 
analyzed with an cozymarie method (Lactate Analyzer 640, 
Roche Bio-Electronics). 
Waived wbhke. The following variables were derived: 
Cardiac index Gudiac outwt&dv surface area: stroke 
volume index &oke volu&Bod~ surface areOf stmke 
work index [(Mean artery presru&- Pttlmooary capillary 
wedge prcwre) x Stroke vdumc index x 0.01361; oxygen 
consumvtion index Grdii index x Arteriovcrmus oxygen 
die&e); mtc-p&w product (Mean artery press& x 
Heart rate); sy&mic v&colar resistance [(M&n artery 
oressore - R&t atrial oressureUCardiac ootoo~l: sod nwo- 
&dial oxy& consum&on [Coronary sinus R&v x (A&+ 
rial oxygen content - Coronary sinus oxygen content)]. Net 
myocardird extraction of lactate and catecholamines = Cor- 
onary sinus Row x (Arterial concentration - Coronary sinus 
concentration). Comoary sinus Raw Iwings cwld not be 
obtained in all patients because ofdiculties with position- 
ing the catheter. 
-The study WBS approv,o by the Ethics Committee of 
the Medical Facultv. Uoiversitv of GBtebora. F’ardcioat- _ . 
ing patients geve informed consent before inclusion in the 
study. 
Statistkal m&ods. Data were analyzed with an IBM 
3081 minicomputer-based SAS statistical software (SAS 
Inc.). Analysis of variance of repeated measures with 
0 6 12 
hlanths of follow up 
Figum 1. Effects on chances in ~xerccise time from tuac!mc L,VW 
ligation; p values denote intergmup companwn hp andlyw of 
variance from baseline to 6 and I? months of follow-up. Data ?re 
mean values 2 SEM. Circks = metopmlol: squarer = piavebo 
unbalanced data (Ill) WBS used. All p values were two-tai!cd. 
All valttes are enpressed as mean values + I SD and in 
figures ix mean vahtrs 2 I SEM. 
One patient in the placebo group, who was withdrawn 
from the study after 6 months of follow-up because of clinical 
deterioration and noncompliance, died of congestive heart 
failure before the end of the study. Another patient in the 
placebo group died of congestive heart failxe after 6 months 
of treatment. and one patient in the metcprolol group died 
suddenly after 6 months of treatment. One patient in the 
placebo group reached a nonfatal end point (need for heart 
transplantation) but maintained therapy and was studied at 
I? months of fallow-up. Hemcdynamic evaluation at 6 
months n’as not petformed in all patients because of ?.d?mn- 
istrdtive reasons. Furthemwre, in the metoproloi goup, one 
patient’s clinical condition vas tao poor to allow supine 
exercise on the catheterization table. and one patient was 
wnble to rnecise because of knee pain 
Functional classification did not chsnge signiticamly dur- 
ing the study period. Maxim.4 exercise tire increased sig- 
nificantly m the metoprolol group by 12 months of treatment 
lFic Il. Eiection fraction increased sienificantlv mcrc in :he ” ” _ 
metoprolol group (21% + 7.30% _c I I. 34% 5 I3 at baseline 
and at 6 and I? months. respectively) compared .with llle 
placebo group (23% + 9.24% t 9,28% t: !2 at baseline and 
al 6 aad I2 months, respeclively). The corresponding p 
values in inr-rgroup comparison of changes from baseline 
wra p = 0.02 al 6 months and p = 0.03 at 12 months. 
Hemodynamic dab. At rest, mclopmlol treatment was 
associated with a sigsilicandy lower heart rate and aa 
increase in systolic arterial pressure and cardiac, stroke 
volume and stroke work indexes (Tables 2 and 3). There 
were shmilar treads during exercise, although the increase in 
cardiac, stroke volume and stmke work indexes in the 
metoprolol group seemed to be more pronounced (Fig. 2). 
Individual data points on stroke work index a1 baseline and 
after I2 months of treatment are shown in Figure 3. There 
was a trend toward lower pulmonary capillary wedge pres- 
sure in the metoprolol group at resl as well as during exercise 
(Fig. 4). Exercise oxygen consumption index increased 
significantly in the metoprolol group compared with the 
placebo group. 
Myoeardial meIabolism. Although the average myocar- 
dial lactate extraction at baseline rest investigation was 
negative in the metoprolol group, suggesting myocardial 
&hernia, there was ao statistical diiereoce between Ihe IWO 
groups (Tables 4 and 5). The negative extrwioo turned to 
positive after 6 and 12 months of treatment (Fig. 51. The 
F&are 2. Effects on cardiac ;wkx 01 rest Md dariq supine bicycle 
subinnrimal exercise; p valet sod symbols as in Fiire I. 
6t z 
0’ I 
test EXCrclY Red EXPrcL5C 
%SCttll~ lYeaLment 
Flgutl. S!mkc work index represented by wdividuaf data points m 
the pleceim (lap) and metopmlol (b&tom) gwps at baseline and 
after I2 months of treatment. Pdlients were investigatnl at rest and 
during supine submaximal exercise. Mean valuer i: SEM are slio 
shown. 
placebo goup had positive extract;on at baseline thnt WBS 
unaltered by therapy. The trends were similar during exer- 
cise, but were not statistically different in group compxi- 
sotts. Coronary sinus Row and mywardial oxySeen conaump- 
lion did not change during the study. By analysis of variance 
the uterial norepinephritte coccentmtion decreased signifi- 
cantly more in the metopmlo) group than in the placebo 
gmupduringfollow-up(p = 0.03). Myocardial metabolism of 
twepinephrine and epinephrine was unaltered by meto- 
protol and placebo treatment. 
Diction 
The patients receiving metoprolol treatment responded 
favorably. as expressed by imprnved hemodynamic status. 
improved ejection fraction, increased myacardial lactate 
extra&n and laxer arterial norepinephtine levels. whereas 
the placebo-treated patients did ttot show any such improve- 
mutt. Hemodynnmic improvement seemed more acccntu- 
ated during exercise. suggesting improved cardiovascular 
racwe. 
Wenodynamii variables. Both rest and exercise hemody- 
namic variables suggested improvement in the metoprolol 
group. whereas the placebo group was unchanged. Lower 
hart r;l!e and filling pressures, accompanied by increased 
stroke volume. stroke work and cardiac indexes are in 
accordance with most previous trials (4,:1-13). The differ- 
ence between the groups tended to he more accectuated 
during cacrcirc. possibly reflecting an improved myocardial 
reserve. Although the patients I our previotis open study 
had worst myucardial function compxed with the pattents 
in this study, the magnitude of improvement was very 
stmilar (61. In the present study there was an increase in 
maximal exercise time in the metaprolol group, but ine 
derived supine submaximal w.ercise load was very similar in 
the two groups during the study investigations. In consider- 
ation of the latter, and the marked improvement in exercise 
hemodynsmic variables found in this study. it might be that 
submaximal performance is a better measure of treatment 
effect. It ip also likely that a submaximal petfomwmce would 
better reflect everyday activities than the orddbary maximal 
exerc,se test. 
Myacnrdial metabolism and ealeeholaminc levels. Afler 
intravenous beta-blocker administration. myocardia! cner~y 
demand is reduced (14). During long-term therapy. meto- 
prolol tended to improve ver!ricular energetics, as reflected 
by increase in stroke work index. ejec:ion fraction and 
arterial pressure. However, the improvement in cerdiac 
function is not sccompanied by increased energy demand, as 
expressed by unchanged myocardial oxygen consumption 
and norepinephrine spillover. Peripheral norepinephrine val- 
ues decreased by 42% in the metoprolol group at rest and 
by 17% during exercise, which is in accordance with our 
previous studg (6). Two other studies have suggested a 
reduction in norepinephrine levels afier beta-blockade in 
patients with dilated cardiomyopalhy, whereas there was no 
eiTec1 in patients with ischemic cardiomyopathy (3.15). 
Bela-blocker therapy. From the results of previous atud- 
ies we have sqgested that the primary short-term effect of 
beta-blockade in heart failure is a reduction in metab& 
demand (11.16). Heart rate, myocardial oxygen consumption 
and coronary sinus Row decreased, whereas tilling oressore, 
ventricular volume and ejecdon fraction were ~~tintained 
(14). The main achievement of beta-blockade mav be lo 
induce this stale of low oxygen demand, whereas systemic 
circulation is maintained on an acceptable level, pending 
recovery of myocardial function. The beneficial effect on 
myocardial function is supported by the findings of relieved 
ischemia. expressed by increased lactate utilization. Along 
with improved myocardial function, higher dosages of beta- 
hlackade are tolerated with maintained systemic circulation. 
This could explain why long-term studies could yield differ- 
ent results than short-term studies (17.18), as well as why 
patients with very poor ventricular function may he ionable 
to recover (19). Furthermore, it would explain why beta- 
blockade therapy must be instituted al low doses and grad- 
ually increased over several weeks. In contrast with inotrop. 
ic agents (X1,21), the inotrapic recovery after beta-blockade 
is not accompanied by M iocrcase in myocardii oxygen 
consumption. Increased beta-receptor den&y and fooctioo 
have been proposed as one reason for improved vcn~ricolar 
fooclion 111.12). In a recent reoort. however. it was saa- 
to increment in beta-adnmueccplor activity (22). Modem 
adrenergic beta-blockers have been used successfully in 
recent trials (3.13,22.23). Bucinddd aad car&ii are 
beta-blockers with vasodilating properties. The vasodilatory 
effect should be of benefit bat makes intetpretatioo of the 
nrulls more diietdl with nsoecl to whether the hemodv- 
aamic effect is doe to beta-blockade or vasodilatioo. Fro; 
the Metoprolol in Dilated Cardiiyopathy Trial (7) it was 
suggested that only 4% of the patients showed intolerance lo 
metopmlol. However, in severely decompcnsatcd patients, 
the intolerance may be as great as SO% (II). This study was 
piformal in potietients with pore idiopathic dilated cardio- 
myopathy. Most previous studies reporting ber&cial etTe.cts 
of beta-blockade treatment have been perfomxd in patients 
with dilated cardiomyopathy. There are more controversies 
with respect to beta-blockade lreatment in conaestive heart 
failore if other etiologies. Some resolts suggest& positive 
effects in ischemic cwdiomvooa~hv (3.6.15). but recent 
reports also suggest positive &&Is ii is&emic patients (24). 
This study adds tiu-ther suppon to the theory that long-term 
beta-bloek~etreatmentconstitutes a therapeutic alternative 
in patients with dilated cardiomyopathy. 
Slody llmit&w. In the pcesent study the test drug was 
withheld before investigations to assess the long-term effects 
Ftgwe 5. EUcctson net myowdid lactate rekase .N rest and during 









of beta-blockade treatment apart from ongoing drug effects. 
To avoid B rebound phenomenon the drug was not withheld 
22 days (25.26). The present datasuppon that this approach 
did not cause any increase in sympathetic drive, as ex- 
pressed by alterations in heart rate or catecholamine levels. 
On the contrary. a lower beta-blockade level may influence 
hemodynamic status. resulting in impairment of diastolic 
function and filling pressures in particular. which in turn 
might intluence exercise tolerance (27,28). Assessment of 
myocardial metabolism by the present method has some 
limitations. A more precise isotope tracer technique was not 
available in our deoxtment at the time of the study (29). 
Further. there wei only myoardial metabolic data from 
five patients during exercise in the metaprolol group at I? 
month follow-up. 
Conclusions. There is accumulated evidence that long- 
term treatment with beta-blockers is useful in congestive 
heart failure. especially that due to dilated cardiomyopathy. 
The present study funher supports the unique therapeutic 
effects of beta-blockers, which are totally different from 
other pharmacologic therapies in heart failure. Protection 
from sympathetic overstimulation is in accordance with the 
fundamentals of contemporary heart failure therapy, with 
internal unloading instead of increased inotropic stimulation. 
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